Drug Profile
CEE 04421
Alternative Names: Analgesic tripeptide (CEE 04421) - CeNeSLatest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator National Institute for Biological Standards and Controls; University of Sao Paulo
- Developer BTG; CeNeS Pharmaceuticals
- Class Analgesics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation; Neuropathic pain; Postoperative pain
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 12 Sep 2002 Discontinued - Preclinical for Inflammation in United Kingdom (PO)
- 12 Sep 2002 Discontinued - Preclinical for Neuropathic pain in United Kingdom (PO)